Malcolm K. Brenner

53.8k total citations · 15 hit papers
492 papers, 35.7k citations indexed

About

Malcolm K. Brenner is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, Malcolm K. Brenner has authored 492 papers receiving a total of 35.7k indexed citations (citations by other indexed papers that have themselves been cited), including 306 papers in Oncology, 222 papers in Immunology and 156 papers in Genetics. Recurrent topics in Malcolm K. Brenner's work include CAR-T cell therapy research (223 papers), Virus-based gene therapy research (148 papers) and Immune Cell Function and Interaction (126 papers). Malcolm K. Brenner is often cited by papers focused on CAR-T cell therapy research (223 papers), Virus-based gene therapy research (148 papers) and Immune Cell Function and Interaction (126 papers). Malcolm K. Brenner collaborates with scholars based in United States, United Kingdom and Germany. Malcolm K. Brenner's co-authors include Cliona M. Rooney, Helen E. Heslop, Gianpietro Dotti, Barbara Savoldo, Robert A. Krance, Adrian P. Gee, Catherine M. Bollard, Hao Liu, Martin Pulé and Stephen Gottschalk and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Malcolm K. Brenner

481 papers receiving 35.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta

1999 1.4k citations Malcolm K. Brenner et al. profile →
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

2011 1.2k citations Gianpietro Dotti, Alana A. Kennedy‐Nasser et al. profile →
A distinct “side population” of cells with high drug efflux capacity in human tumor cells

2004 1.0k citations Malcolm K. Brenner et al. profile →
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

1995 942 citations Cliona M. Rooney, Catherine Y. Ng et al. profile →
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

2008 919 citations Barbara Savoldo, Gianpietro Dotti et al. profile →
Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma

2011 882 citations Barbara Savoldo, Gianpietro Dotti et al. Blood profile →
Infusion of Cytotoxic T Cells for the Prevention and Treatment of Epstein-Barr Virus–Induced Lymphoma in Allogeneic Transplant Recipients

1998 859 citations Cliona M. Rooney, Catherine Y. Ng et al. Blood profile →
CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

2011 794 citations Barbara Savoldo, Carlos A. Ramos et al. profile →
Gene-marking to trace origin of relapse after autologous bone-marrow transplantation

1993 735 citations Malcolm K. Brenner, Robert A. Krance et al. profile →
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

2009 589 citations Helen E. Heslop, Catherine M. Bollard et al. Blood profile →
An inducible caspase 9 safety switch for T-cell therapy

2005 560 citations Gianpietro Dotti, Malcolm K. Brenner et al. Blood profile →
Design and development of therapies using chimeric antigen receptor‐expressing T cells

2013 404 citations Gianpietro Dotti, Stephen Gottschalk et al. profile →
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma

2017 391 citations Barbara Savoldo, Olga Dakhova et al. profile →
Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins

2013 384 citations Catherine M. Bollard, Stephen Gottschalk et al. Journal of Clinical Oncology profile →
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

2025 14 citations Sandhya Sharma, Mae Woods et al. profile →

Peers

Countries citing papers authored by Malcolm K. Brenner

Since Specialization

Citations

This map shows the geographic impact of Malcolm K. Brenner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malcolm K. Brenner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malcolm K. Brenner more than expected).

Fields of papers citing papers by Malcolm K. Brenner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Malcolm K. Brenner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malcolm K. Brenner. The network helps show where Malcolm K. Brenner may publish in the future.

Co-authorship network of co-authors of Malcolm K. Brenner

This figure shows the co-authorship network connecting the top 25 collaborators of Malcolm K. Brenner. A scholar is included among the top collaborators of Malcolm K. Brenner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Malcolm K. Brenner. Malcolm K. Brenner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Binary oncolytic adenovirus in combination with HER2-specific autologous CAR VST for treatment of advanced HER2-positive solid tumors (VISTA). 2024 ·Journal of Clinical Oncology ·Shalini Makawita, (unknown), (unknown), Caroline E. Porter, Amanda Rosewell Shaw, (unknown), Mae Woods, Tao Wang, Bambi Grilley, Helen E. Heslop, Malcolm K. Brenner, Masataka Suzuki	6
2	OFF‐THE‐SHELF CD30.CAR‐MODIFIED EPSTEIN‐BARR VIRUS‐SPECIFIC T CELLS (CD30.CAR EBVSTS) PROVIDE A SAFE AND EFFECTIVE THERAPY FOR PATIENTS WITH HODGKIN LYMPHOMA (HL) 2023 ·Hematological Oncology ·Carlos A. Ramos, David H. Quach, Premal Lulla, Rayne H. Rouce, Sandhya Sharma, (unknown), Nazila Nouraee, (unknown), (unknown), Sachin G. Thakkar, Birju Mehta, (unknown), Emily M. Hsieh, Huimin Zhang, Bambi Grilley, Natalia Lapteva, Malcolm K. Brenner, Helen E. Heslop, Cliona M. Rooney	8
3	Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies 2019 ·Blood ·LaQuisa Hill, Rayne H. Rouce, Tyler S. Smith, Lina Yang, Madhuwanti Srinivasan, Huimin Zhang, (unknown), Birju Mehta, Olga Dakhova, (unknown), Bambi Grilley, Helen E. Heslop, Malcolm K. Brenner, Maksim Mamonkin	51
4	A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia 2018 ·Clinical Cancer Research ·Gunilla Enblad, Hannah Karlsson, (unknown), Jessica Wenthe, Tanja Lövgren, Rose‐Marie Amini, Kristina Wikström, Magnus Essand, Barbara Savoldo, Heléne Hallböök, Martin Höglund, Gianpietro Dotti, Malcolm K. Brenner, Hans Hagberg, Angelica Loskog	207
5	Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment 2018 ·Cancer Discovery ·Sujita Sukumaran, Norihiro Watanabe, Pradip Bajgain, (unknown), Somala Mohammed, William E. Fisher, Malcolm K. Brenner, Ann M. Leen, Juan F. Vera	106
6	Armed Oncolytic Adenovirus–Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors 2017 ·Cancer Research ·Kiyonori Tanoue, Amanda Rosewell Shaw, Norihiro Watanabe, Caroline Porter, (unknown), Stephen Gottschalk, Malcolm K. Brenner, Masataka Suzuki	180
7	Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells 2017 ·Cancer Discovery ·Thomas Shum, Bilal Omer, Haruko Tashiro, Robert L. Kruse, Dimitrios L. Wagner, Kathan Parikh, Zhongzhen Yi, Tim Sauer, Daofeng Liu, Robin Parihar, Paul Castillo, Hao Liu, Malcolm K. Brenner, Leonid S. Metelitsa, Stephen Gottschalk, Cliona M. Rooney	220
8	Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies 2017 ·Cancer Immunology Research ·Maksim Mamonkin, Malini Mukherjee, Madhuwanti Srinivasan, Sandhya Sharma, Diogo Gomes‐Silva, Feiyan Mo, Giedre Krenciute, Jordan S. Orange, Malcolm K. Brenner	79
9	Chimeric Antigen Receptor (CAR) T Cell Therapy for CD7-Positive Acute Myeloid Leukemia 2017 ·Blood ·Diogo Gomes‐Silva, Haruko Tashiro, Madhuwanti Srinivasan, Premal Lulla, Malcolm K. Brenner, Maksim Mamonkin	2
10	Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity 2014 ·Clinical Cancer Research ·Alana A. Kennedy‐Nasser, Stephanie Ku, (unknown), Yasmin Hazrat, Meng-Fen Wu, Hao Liu, Jos Melenhorst, A. John Barrett, Sawa Ito, Aaron E. Foster, Barbara Savoldo, Eric Yvon, George Carrum, Carlos A. Ramos, Robert A. Krance, Kathryn Leung, Helen E. Heslop, Malcolm K. Brenner, Catherine M. Bollard	145
11	Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation 2013 ·Blood ·Ann M. Leen, Catherine M. Bollard, Adam Mendizabal, Elizabeth J. Shpall, Paul Szabolcs, Joseph H. Antin, Neena Kapoor, Sung‐Yun Pai, Scott D. Rowley, Partow Kebriaei, Bimalangshu R. Dey, Bambi Grilley, Adrian P. Gee, Malcolm K. Brenner, Cliona M. Rooney, Helen E. Heslop	392
12	Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition 2013 ·Clinical Cancer Research ·Serena Perna, Daria Pagliara, Aruna Mahendravada, Hao Liu, Malcolm K. Brenner, Barbara Savoldo, Gianpietro Dotti	115
13	Interleukin 15 Provides Relief to CTLs from Regulatory T Cell–Mediated Inhibition: Implications for Adoptive T Cell–Based Therapies for Lymphoma 2012 ·Clinical Cancer Research ·Serena Perna, Biagio De Angelis, Daria Pagliara, (unknown), Lan Zhang, Aruna Mahendravada, Helen E. Heslop, Malcolm K. Brenner, Cliona M. Rooney, Gianpietro Dotti, Barbara Savoldo	63
14	Immunotherapy of Metastatic Melanoma Using Genetically Engineered GD2-Specific T cells 2009 ·Clinical Cancer Research ·Eric Yvon, Michele Del Vecchio, Barbara Savoldo, Valentina Hoyos, Aurélie Dutour, Andrea Anichini, Gianpietro Dotti, Malcolm K. Brenner	113
15	Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells 2003 ·Blood ·Eric Yvon, Stéphane Vigouroux, Raphaël F. Rousseau, Ettore Biagi, Persis Amrolia, Gianpietro Dotti, Hans-Joachim Wagner, Malcolm K. Brenner	128
16	Increased Transduction Efficiency of Primary Hematopoietic Cells by Physical Colocalization of Retrovirus and Target Cells 1998 ·Journal of Hematotherapy ·(unknown), Koichi Moriwaki, Dagmar Dilloo, Thomas Hoffmann, (unknown), Hans Erik Johnsen, Malcolm K. Brenner, Helen E. Heslop	9
17	Gene Marking and Gene Therapy for Transplantation Medicine 1996 ·Journal of Hematotherapy ·Dagmar Dilloo, Donna Rill, Michael E. Grossmann, Thasia Leimig, Malcolm K. Brenner	5
18	Production of Genetically Modified Epstein-Barr Virus-Specific Cytotoxic T Cells for Adoptive Transfer to Patients at High Risk of EBV-Associated Lymphoproliferative Disease 1995 ·Journal of Hematotherapy ·(unknown), Catherine Y. Ng, Helen E. Heslop, Martha Holladay, (unknown), (unknown), Susan K. Loftin, (unknown), Malcolm K. Brenner, Cliona M. Rooney	103
19	Gene Marking to Improve the Outcome of Autologous Bone Marrow Transplantation 1994 ·Journal of Hematotherapy ·Malcolm K. Brenner, Donna Rill	16
20	Intravenous gammaglobulin treatment in patients with hypogammaglobulinaemia. 1984 ·BMJ ·(unknown), Malcolm K. Brenner, I. D. Hill, G. L. Asherson, Aaron Webster	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact